# Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/tislelizumab-versus-chemotherapy-as-second-line-treatment-for-advanced-or/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Lin Shen,Ken Kato,Sung‐Bae Kim,Jaffer A. Ajani,Kuaile Zhao,Zhiyong He,Xinmin Yu,Yongqian Shu,Qi Luo,Jufeng Wang,Zhendong Chen,Zuoxing Niu,Longzhen Zhang,Tienan Yi,Jong‐Mu Sun,Jianhua Chen,Guohua Yu,Chen‐Yuan Lin,Hiroki Hara,Qing Bi,Taroh Satoh,Roberto Pazo-Cid,Hendrick-Tobias Arkenau,Christophe Borg,Florian Lordick,Liyun Li,Ningning Ding,Aiyang Tao,Jingwen Shi,Eric Van Cutsem,for the RATIONALE-302 Investigators |
| Citations | 315 |
| DOI | 10.1200/jco.21.01926 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.21.01926?role=tab |
| OpenAlex ID | https://openalex.org/W4224213460 |
| PMID | 35442766 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Jong‐Mu Sun](https://scholariq.org/researchers/jong-mu-sun/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

## Paper topics

- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal and Anal Carcinomas](https://scholariq.org/topics/colorectal-and-anal-carcinomas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.